L'entreprise Sud Coréenne Hyundai a déclaré que ses scientifiques ont développé un antiviral universal qui peut guérir toutes les infections virales. Ce nouveau antiviral est éfficace contre tous les variants de la Covid et meme contre la variole du singe , l'ébola, l'hépatite C et le VIH. Des études cliniqués ont été approuvés par le FDA aux États-Unis pour traiter la covid et la variole du singe.
Le nouveau antiviral peut éradiquer meme des infections virales chroniques car il agit comme un inducteur d'autophagie, donc il tue les cellules infectées.
Selon l'entreprise Hyundai, le cp-covi03 est un ''grame changer'' dans le traitement des infections virales.
The birth of a universal antiviral drug with a mechanism applicable to all viral infections is approaching. This antiviral agent, developed in Korea, has an innovative 'viral removal' mechanism applicable to all viruses, unlike existing antiviral agents that target only specific viruses. It is expected to open a new chapter in the world's antiviral drug history if it produces valid clinical results.
Hyundai Bioscience has announced that phase 2 clinical trial of CP-COV03 for COVID-19 patients has begun. CP-COV03 is an orally administered antiviral drug (active ingredient: niclosamide) developed as a universal treatment for viral diseases including COVID-19.
CP-COV03 is an innovative broad-spectrum antiviral agent with a pharmacological action that helps human cells to remove viruses by promoting 'autophagy' mechanism, in which cells recognize the virus as a foreign substance and remove it themselves.
If CP-COV03 is confirmed to be effective against COVID-19 in this clinical study, it means that a universal antiviral drug is born not only for COVID-19 and its variants, but also for almost all other viruses such as influenza, hepatitis, AIDS, Ebola, and herpes. Expected to gain the focus of the scientific communities, a favorable study result may become a 'flare shot' to signal the birth of the universal antiviral drug.
Le nouveau antiviral peut éradiquer meme des infections virales chroniques car il agit comme un inducteur d'autophagie, donc il tue les cellules infectées.
Selon l'entreprise Hyundai, le cp-covi03 est un ''grame changer'' dans le traitement des infections virales.
The birth of a universal antiviral drug with a mechanism applicable to all viral infections is approaching. This antiviral agent, developed in Korea, has an innovative 'viral removal' mechanism applicable to all viruses, unlike existing antiviral agents that target only specific viruses. It is expected to open a new chapter in the world's antiviral drug history if it produces valid clinical results.
Hyundai Bioscience has announced that phase 2 clinical trial of CP-COV03 for COVID-19 patients has begun. CP-COV03 is an orally administered antiviral drug (active ingredient: niclosamide) developed as a universal treatment for viral diseases including COVID-19.
CP-COV03 is an innovative broad-spectrum antiviral agent with a pharmacological action that helps human cells to remove viruses by promoting 'autophagy' mechanism, in which cells recognize the virus as a foreign substance and remove it themselves.
If CP-COV03 is confirmed to be effective against COVID-19 in this clinical study, it means that a universal antiviral drug is born not only for COVID-19 and its variants, but also for almost all other viruses such as influenza, hepatitis, AIDS, Ebola, and herpes. Expected to gain the focus of the scientific communities, a favorable study result may become a 'flare shot' to signal the birth of the universal antiviral drug.
Commentaire